National Quality Initiatives Amplify Health Systems’ Focus on Effective Glycemic Management as Glytec Fortifies Industry Leadership Position Strategic Partnerships, Product Innovation and Customer Expansion Underpin Insulin Dosing Technology Company’s Sustained Growth WALTHAM, Mass. (March 15, 2022) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced that it has significantly expanded the deployment of …
Glytec And Nebraska Medicine Establish Strategic Partnership to Advance Patient Safety and Innovation Around Insulin Management Leader in Endocrinology Research Implements eGlycemic Management System Across Hospitals, Dedicates Resources Towards Research and Development WALTHAM, Mass. (January 25, 2022) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced a new strategic partnership with Nebraska …
Glytec and Roche Announce Strategic Partnership to Bring Digital Health Innovation in Glycemic Decision Support to the Hospital Bedside As CMS Creates an Emphasis on Hyperglycemia and Hypoglycemia Rates in the Hospital, Partnership Aims to Transform the Standard of Care WALTHAM, MASS. (January 12, 2022) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today …
Glytec Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture and Meet Compliance Requirements HITRUST CSF Certification validates Glytec is committed to meeting key regulations and protecting sensitive information. WALTHAM, MASS. (January 4, 2022) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced that Glytec’s eGlycemic Management System®, including Glucommander™, has …
Glytec Awarded First Patient Safety Solutions Agreement with Premier Glytec named sole supplier of insulin management software for Premier’s network of more than 4,400 U.S. hospitals and 225,000 providers WALTHAM, MASS. (October 26, 2021) –Glytec – the only provider of cloud-based insulin management software across the continuum of care, today announced that it has been awarded a group purchasing agreement …
Healthcare Industry Leaders Unite Around Patient Safety at Glytec’s Inaugural Conference on Glycemic Innovation and Collaboration Conference Identifies Key Strategies and Actionable Insights for Hospitals to Optimize Glycemic Management Ahead of New CMS Core Measures WALTHAM, MASS. (August 31, 2021) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today revealed details about its …
Glytec Research Presented at American Diabetes Association’s 81st Scientific Sessions Shows Low Hypoglycemia for Adults with T1D Treated with eGlycemic Management System Largest study to analyze T1D Patients With and Without DKA finds Glucommander insulin management software can safely keep blood glucose levels in range WALTHAM, MASS. (June 22, 2021) – Glytec, the only provider of cloud-based insulin management software …
AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.
In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
Results of a nationwide survey indicate most hospitals do not employ best practices in glucose control, which leads to increased safety risks, higher readmission rates and significantly greater costs.
According to a recent survey, more than 75% of U.S. hospitals employ an outdated form of insulin therapy inconsistent with recommendations by the American Diabetes Association, American Association of Clinical Endocrinologists, Society of Hospital Medicine and other authoritative sources.
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.
Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System® versus usual care across multiple studies.
In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.
A diabetes webinar hosted by the American Hospital Association and sponsored by Glytec showcased why hypoglycemia prevention is imperative to the safety of patients and to the economics of healthcare delivery.
Featured speakers, Dr. Richard Pratley of Florida Hospital System and Dr. Steven Edelman of UC San Diego Health, recently delivered a unified message to several hundred senior healthcare professionals attending an American Hospital Association webinar: Hypoglycemia [low blood sugar] in the hospital is a major patient safety risk with significant clinical and financial implications. A case study presented by Pratley further revealed that insulin-managed patients who experience severe hypoglycemia, or blood sugar less than 40 mg/dL, have longer stays, higher readmission and mortality rates, and an overall cost of care $10,405 greater than patients whose blood sugar remains in the normal range.
The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health.
The population of hospitalized patients with diabetes is on the rise, as is the cost and intensity of their care. Glytec is partnering with the American Hospital Association to deliver a webinar that brings greater attention and awareness to reducing risks and improving safety for patients with diabetes.
Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.
With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.
The popular eBook showcases clinical and financial implications of hypoglycemia, a common occurrence among hospitalized patients that costs the average hospital $1.5 to $5.6 million a year, or more.
Hypoglycemia in the hospital is common, costly, extremely serious and largely preventable, but many c-suite and business office executives are unaware of what it is, why it occurs or the significant impact it has on patient safety, outcomes and economics. A new eBook from Glytec, offered free of charge at the company’s website, shines a light on critical concerns surrounding hypoglycemia and helps healthcare organizations understand how to mitigate risks and initiate optimal prevention strategies. Availability of the eBook is especially timely given the hypoglycemia quality measure currently under development by the Centers for Medicare & Medicaid Services (CMS).
New Mexico’s only academic medical center will soon implement Glytec’s evidence-based eGlycemic Management System® for best practices in insulin therapy management.
University of New Mexico Hospital, already a distinguished leader in diabetes care, is partnering with Glytec to achieve the highest levels of quality and safety for hospitalized patients who require insulin therapy. Using Glytec’s eGlycemic Management System®, the Albuquerque-based academic medical center will not only introduce greater standardization and systemization around best practices in glycemic management, but will aim to realize the very significant goal of eliminating severe hypoglycemia.
Atlanta-based Piedmont Healthcare will implement Glytec’s eGlycemic Management System® across all acute care facilities.
Standardizing and personalizing insulin therapy management for hospitalized patients is a goal Piedmont Healthcare is poised to achieve through expanded use of Glytec’s eGlycemic Management System®, or eGMS®. The not-for-profit healthcare system currently uses eGMS® at Piedmont Atlanta Hospital, Piedmont Newnan Hospital and Piedmont Athens Regional Medical Center. Based on a new agreement, Piedmont Healthcare will implement eGMS® at Piedmont Henry Hospital, Piedmont Fayette Hospital, Piedmont Newton Hospital and Piedmont Mountainside Hospital.
New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.
A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.